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arotid Plaque Assessment
Bumpy Road to
mproved Risk Prediction
e congratulate Nambi et al. (1) on their study of improved
rediction of coronary heart disease (CHD) risk by including the
nformation on carotid plaque presence in the ARIC (Atheroscle-
osis Risk In Communities) study. Inclusion of plaque in the risk
rediction model reclassified over 10% of individuals into the
igher risk category beyond the levels of carotid intima-media
hickness (CIMT) and traditional risk factors. The study is
ignificant because the ARIC investigators acknowledge that
mall, nonstenotic carotid plaque might be a different phenotype of
therosclerosis, carrying an important contribution to the vascular
isk beyond CIMT. Plaque presence was defined if 2 of the
ollowing 3 criteria were met: CIMT 1.5 mm, abnormal wall
hape, and abnormal wall texture. This is a somewhat novel
pproach, because Dr. Ward A. Riley (a reputable CIMT and
RIC investigator who unfortunately is no longer with us) believed
hat “whatever is between intima and media represents CIMT” (Dr.
ard A. Riley, personal communication, 2001). In the recent CIMT
eta-analysis (2) very little is mentioned regarding the difference
etween CIMT and plaque and the prognostic importance of carotid
laque. Carotid plaque is a distinctive phenotype of atherosclerosis,
ost likely is not a simple continuum of CIMT progression, and
redicts stroke and CHD risk better than CIMT (3).
Interestingly, the ARIC investigators report that slightly more
ubjects were reclassified to a lower risk group (approximately 12%)
han to a higher risk group (approximately 11%) after adding
IMT and plaque information. No one was reclassified from the
ow-risk group (5% estimated 10-year CHD risk) to the high-
isk group (20% estimated 10-year CHD risk). In the NOMAS
Northern Manhattan Study)—a prospective, multi-ethnic, urban,
opulation-based cohort—the presence of small, nonstenotic ca-
otid plaque reclassified 44% of the low-risk individuals (10%
stimated 10-year CHD risk) to the intermediate-risk category
10% to 20% estimated 10-year risk) (4). In addition, approxi-
ately 12% of subjects in a lower risk category had a 10-year
stimated risk of 25%, which reclassified these individuals to high
isk (20% estimated 10-year risk). None of the individuals was
eclassified to a lower risk category after adding information on
laque presence—as opposed to ARIC. The NOMAS results are,
owever, hardly ever cited, possibly because they appeared in
eurology, a journal mostly neglected by non-neurologists. There-
ore, “the intriguing hypothesis” raised by Stein and Johnson in the
ditorial Comment (5) that “carotid ultrasound could be used to
dentify persons at lower than apparent risk who might be
andidates for less intensive interventions” might be simply rejected
f data from NOMAS and others (6) are considered. sNevertheless, less intensive intervention should not be advised
ccording to ultrasound imaging data for individuals otherwise
stimated at intermediate-to-high vascular risk on the basis of
raditional vascular risk factors. We believe these individuals
hould be treated aggressively, irrespective of a possible lower risk
ccording to the information obtained by the levels of biomarkers,
ither imaging or soluble.
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eply
e thank Drs. Rohatgi and Berry and Rundek and Salameh for
heir interest in our communication regarding the use of carotid
ntima media thickness (CIMT) and plaque to improve coronary
eart disease (CHD) risk prediction in the ARIC (Atherosclerosis
isk In Communities) study (1).
It is important to note that our study tested whether CIMT and
laque can help better predict CHD risk, but it does not have the
bility to offer guidance on treatment strategies on the basis of such
risk prediction scheme. Therefore, we completely agree with Drs.
undek and Salameh that, on the basis of our data alone, one
hould not decide on decreasing interventions. However, we feel
hat such a strategy should be prospectively tested, as has been
uggested by Drs. Stein and Johnson in the editorial that accom-
anied our publication (2). Drs. Rundek and Salameh also discuss
heir excellent contribution from the NOMAS (Northern Man-
attan Study) (3), in which they examined the value of adding
laque to the Framingham risk prediction score (FRS). However,
ome important facts/differences need to be considered.
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September 21, 2010:1065–70Anytime a new marker is added to a risk prediction schema,
ndividuals will have to be (re)classified into higher- and lower-risk
roups. It is this reclassification that allows us to evaluate the utility
f the marker, including its ability to discriminate between those
ho have disease and those who do not have disease. For example,
n our analysis, values were coded for the presence or absence of
laque and for the CIMT group (i.e., 25th percentile, 25th to
5th percentile, and75th percentile), and then this was added to
he traditional risk scores to get the new predicted risk. Having no
laque and a CIMT25th percentile is favorable and might result
n an individual remaining in the same risk group or being
eclassified to a lower-risk group. This would depend on the
ontribution of the traditional risk factors to the individual’s risk.
herefore, we are not clear as to how no one was reclassified to a
ower-risk group in Dr. Rundek’s analysis. Furthermore, in the
ther analysis cited by them, Bard et al. (4) evaluated individuals
ith “intermediate FRS” (6% to 19%, 10-year predicted CHD risk
n their analysis) and described that adding CIMT and plaque area
eclassified individuals to both “high”- and “low”-risk groups.
owever, this analysis could not test whether the reclassification
as accurate, because they did not have incident CHD event data.
Another difference between our analysis and Dr. Rundek’s analysis
as that stroke was included as an end point in her analysis, and 121
f the 319 events were strokes. Although there is a Framingham
ardiovascular disease risk score that includes stroke as an end point,
he CHD FRS does not include stroke as an end point. The risk score
sed by Dr. Rundek in her analysis seems to be the CHD risk score
nd hence might not have been able to adequately predict risk when
troke was included as an end point.
Drs. Rohatgi and Berry discuss our presentation of the net
eclassification index (NRI) statistic and suggest that the information
rovided is insufficient to evaluate the clinical utility of the test. We
isagree. First, NRI is only 1 of many test statistics that are required
and presented in our paper) to evaluate clinical utility of a risk
redictor. Second, we believe that both upward (to a higher-risk
roup) and downward (to a lower-risk group) reclassification is
linically relevant. The format of reclassification we have presented
as been used by others as well (5). However, we agree that the format
hey request is another valid and informative way to present the data
nd have presented the same in Table 1 here.
For the calculation of “clinical NRI,” 5% to 20% was considered
s 1 risk group, and reclassification to20% risk was considered an
pward reclassification, whereas reclassification to 5% risk was
onsidered a downward reclassification. Incidentally, if we used
0% to 20% as the intermediate-risk group, the clinical NRI was
8.2%.
We disagree with Drs. Rohatgi and Berry that treatment
hanges can only result when an individual is reclassified to20%,
ecause Adult Treatment Panel III clearly identifies “optional”
oals for both high-risk and intermediate-risk individuals. How-
ver, as previously noted, our main effort was to evaluate the ability
f CIMT and plaque in improving risk prediction and not to direct
herapy, which should be tested formally.
Finally, FRS has been developed for both “hard CHD” and
total CHD” end points. We included all CHD end points except
ngina to be able to compare the NRI with other markers such as
igh-sensitivity C-reactive protein (5). In fact, Pencina et al. (6), in
he example they provided in their original description of NRI,
ncluded angina and coronary insufficiency in evaluating the additive
ffects of high-density lipoprotein cholesterol in CHD risk prediction.
f we used only hard CHD end points, the NRI for the overall group,en and women was 5.0%, 8.6%, and 5.3%, whereas the clinical NRI
as 14.0%, 16.4%, and 16.5%, respectively.
We also would like to point out an error we noted in Table 5 of
ur paper (1). The value in the last row (i.e., Kaplan-Meier
stimates for “All”) of Table 5 under the column “10% to 20%”
hould read “13” and not “3” as listed. We regret this error.
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Table 1
Net Reclassification Index and Clinical Net
Reclassification Indices Among Those With and
Without Incident Coronary Heart Disease Events
Population
Reclassification
Index Among Those
With Events
Reclassification
Index Among Those
Without Events
Net
Reclassification
Index
Men 3.2% 5.7% 8.9%
Women 9.6% 0.1% 9.8%
Overall 7.6% 2.3% 9.9%
Clinical
Reclassification
Index Among Those
With Events
Clinical
Reclassification
Index Among Those
Without Events
Clinical Net
Reclassification
Index
Men 9.5% 6.8% 16.4%
Women 9.7% 15.6% 25.4%
Overall 10.4% 11.3% 21.7%72, discussion 207–12.
